Simmi Wiggins
Global Director, Medical Affairs, Dermatology Indications Sanofi
Simmi Wiggins is Global Director, Medical Affairs for Dermatology Indications at Sanofi, working at the intersection of immuno-dermatology science, evidence generation, and market development. She specialises in advancing strategy beyond symptom control -focusing on disease modification, immune “normalisation”, and the systemic nature of type-2 inflammation across skin, lung, gut and allergy. Simmi brings a pragmatic view on regulatory variability across countries, cross-disease value communication, and the opportunities (and limits) of AI for clinical design, data synthesis, and faster insight generation across large real-world datasets.
Seminars
Thursday 21st May 2026
Designing Trials for Type-2 Inflammation as a Systemic Construct: Rethinking Single-Organ Drug Development
10:30 am
- Re-engineering development programmes to demonstrate efficacy across interconnected type-2–driven diseases (dermatology, pulmonology, allergy, GI), avoiding siloed organ-by-organ strategies that dilute evidence and delay approval
- Determining the regulatory bar for cross-disease indications, including lessons from countries like Spain that have granted Type-2 inflammation approvals and what constitutes sufficient evidence of systemic immune normalisation
- Redefining recruitment and endpoint strategy by identifying shared mechanistic markers, designing trans-organ inclusion criteria, and crafting commercial and medical narratives that communicate a unified systemic mechanism
Wednesday 20th May 2026
Designing AI-Enabled Clinical Trials: Increasing Efficiency Across Protocol Design, Data Handling & Execution
1:30 pm
- Integrating AI to streamline clinical trial protocol development and reduce operational complexity
- Applying AI for real-time data handling, QC, and monitoring across dermatology studies
- Using multimodal AI to detect treatment inertia, physician behaviour, bottlenecks in access pathways
- Potential for AI-supported creation of retrospective evidence for regulatory submissions
